Ensure your covered population has access to Wegovy Undeniably powerful weight loss in both the pill and pen 1-3 Proven weight-loss efficacy in both pen and pill formats for adults with obesity or overweight with at least one weight-related comorbidity, in addition to diet and exercise Major cardiovascular event risk reduction that matters The only GLP-1 RA indicated for weight loss proven to help prevent life-threatening CV events for adults with established CVD and either overweight or obesity, along with diet and exercise 1,4,5 More ways to start than ever before Available in a once-daily pill or once-weekly pen , with broad access options for your commercially insured population and the lowest Wegovy self-pay offer yet 6 Explore the study information under Efficacy & Safety CV, cardiovascular
Investigation 122 (1), 388402
Also, liraglutide (NCT02953665), lixisenatide (NCT03439943), exenatide (NCT04305002), sustained release exenatide PT320 (NCT04269642) and a pegylated form of exenatide, NLY01 (NCT04154072), are all undergoing clinical investigation in Parkinsons disease
Tirzepatide: a Novel, once-weekly dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] Broad RC, Bonneau JP, Hellens RP, Johnson AAT